Chronic active Epstein–Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation
- 1 March 2002
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 29 (6) , 531-533
- https://doi.org/10.1038/sj.bmt.1703392
Abstract
We report a pediatric case of CAEBV and T cell-based Hodgkin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling. The diagnosis of CAEBV was made from clinical signs and the presence of the EBV genome in PBMC and tumor cells. Conditioning with busulfan (BU) + etoposide (VP16) + cyclophosphamide (CY) was effective and well tolerated. EBV was totally eradicated by 3 months after allo PBSCT. Although she suffered from chronic GVHD of the liver, she has been well and free of disease for 47 months since PBSCT. We suggest allo PBSCT for CAEBV as a potent therapeutic strategy for eradication of the EBV genome and allowing immunological reconstitution.Keywords
This publication has 10 references indexed in Scilit:
- Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein–Barr virus infectionBone Marrow Transplantation, 2000
- Interferon-α Therapy for Chronic Active Epstein-Barr Virus InfectionJournal of Pediatric Hematology/Oncology, 1998
- Successful treatment of Epstein–Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantationBone Marrow Transplantation, 1998
- Bone marrow transplatation for Epstein-Barr virus-related clonal T cell proliferation associated with hemophagocytosisBone Marrow Transplantation, 1997
- Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemiaThe Lancet, 1996
- Establishment of anti-Epstein–Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infectionClinical and Experimental Immunology, 1996
- Ganciclovir for chronic active Epstein-Barr virus infectionThe Lancet, 1993
- Clinicopathological Spectrum of Epstein-Barr Virus-Associated T Cell MalignanciesLeukemia & Lymphoma, 1992
- SUCCESSFUL TREATMENT OF CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION WITH RECOMBINANT INTERLEUKIN-2The Lancet, 1987
- Chronic, symptomatic Epstein-Barr virus infectionsImmunology Today, 1986